Affimed Therapeutics AG expands clinical development team
In preparation for the clinical entry of its first product candidate Affimed Therapeutics AG expands its development team with an experienced expert. Effective immediately, Dr Christian Hucke takes over responsibility for planning and implementation of the clinical development programs at Affimed. Dr Hucke joins Affimed from Grünenthal GmbH.
Christian Hucke has long-term experience in conception and management of clinical studies. At Grünenthal he had the overall responsibility for a worldwide Phase-III-Study in pain therapy of cancer patients as well as a Proof-of-Concept-Phase-II-Study against diabetic polyneuropathy. Previously, Dr Hucke worked in clinical drug development at PAION Deutschland GmbH and the ClinPharmCologne TROPON GmbH. In the course of his various activities he was responsible for more than 12 Phase-I, II- and III-Studies in diverse indications. Christian Hucke is a doctor in biology with focus on immunology. After graduating and obtaining a doctorate degree in Düsseldorf he worked at the institute of Medical Microbiology at the Heinrich-Heine University of Düsseldorf.
Dr Rolf H. Günther, CEO of Affimed, commented: "The year 2010 will be a very important and decisive year for Affimed: both our lead-products will enter the clinic in 2010. In this crucial phase, Christian Hucke will hold a key position in our development team."
Other news from the department people
